AWM
DSGN icon

Avior Wealth Management’s Design Therapeutics DSGN Stock Holding History

Avior Wealth Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$28 – 2670
2024
Q1 		$28 Buy
+7
New +$19 ﹤0.01% 3621

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avior Wealth Management's DSGN Position: Q2 2024 in Review

Avior Wealth Management sold out of Design Therapeutics (DSGN) in Q2 2024, closing a stake of 7 shares — an estimated $28 sold.

Avior Wealth Management first reported a position in DSGN in Q1 2024 and held it in 1 quarter. The position peaked at $28 in Q1 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q2 2024.

  • Avior Wealth Management reported no remaining Design Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 7 Design Therapeutics shares in Q2 2024, an estimated $28.
  • Avior Wealth Management first reported a position in Design Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Design Therapeutics position peaked at $28 in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.